TABLE 3.
Treatment response and refractory/relapse according to initial chemotherapy regimen (n = 57).
| Regimen | n, (%) | Best response, n | Refractory/relapse, n | |||
|---|---|---|---|---|---|---|
| NAD | PR | SD | PD | |||
| Special‐C 14 | 36 (63.1) | 20 | 12 | 3 | 1 | 14 |
| Cytarabine 13 , 20 | 10 (17.5) | 6 | 3 | 0 | 1 | 5 |
| JLSG‐02 10 | 3 (5.3) | 3 | 0 | 0 | 0 | 0 |
| Cladribine 11 | 3 (5.3) | 1 | 0 | 0 | 2 | 2 |
| Other | 5 (8.8) | 3 | 1 | 1 | 0 | 3 |
| Total | 33 | 16 | 4 | 4 | 24 | |
Abbreviations: Special‐C, the Japan LCH study group Special‐C regimen, comprising vinblastine, prednisolone, methotrexate and 6‐mercaptopurine; JLSG‐02, the Japan LCH study group‐02 regimen; NAD, no active disease; PD, progression disease; PR, partial response; SD, stable disease.